In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Vivo Infographics

Top 10 Best-Selling Drugs Of 2020

One hundred billion dollars. That is the combined revenue of the top 10 pharmaceuticals in 2020, marking the first year in which this threshold has been crossed. AbbVie’s Humira easily retained its lead in 2020 with $20.3bn in sales. Gilead Sciences’ HIV triple combo Biktarvy was the fastest climber, entering the top 10 in eighth place after 53.2% growth in a year, while Avastin, Enbrel and Rituxan fell out of the list.

Snapshot: May Highlights

A selection of articles you might have missed from May 2021, including exclusive interviews with industry leaders and a deeper dive into drug development and R&D.

30 Life Sciences Leaders To Watch In 2021

30 Rising Leaders who are making waves and challenging traditional structures across the biopharma and medtech sectors. In Vivo's 2021 list also includes industry stars that have raised their game in response to the COVID-19 pandemic. 

Snapshot: April Highlights

A selection of articles you might have missed from April 2021, including exclusive interviews with industry leaders and a deeper dive into drug development and R&D.

The Growing GLP-1 Therapy Market

Novo Nordisk was not the first biopharmaceutical company to launch a GLP-1 therapy into the market for type 2 diabetes. In fact, Amylin Pharmaceutials’ and Eli Lilly’s Byetta (exenatide) beat Novo’s Victoza (liraglutide) to market by a full five years.  

Snapshot: March Highlights

A selection of articles you might have missed from March 2021, including exclusive interviews with industry leaders and a deeper dive into drug development and R&D.

SPACs Surge In 2020

Despite the COVID-19 chaos felt by many industries in 2020, biopharma IPOs recorded a banner year – including a marked rise in the use of special purpose acquisition companies (SPACs), also known as blank check companies. 

Cancer Deals That Grabbed Headlines In 2020

Despite the COVID-19 pandemic, 2020 has seen a hectic pace of cancer deal-making, including the two largest biopharma M&A deals of the year and 24 deals with upfront value of at least $100m.

Numbers Crunched: Reviewing Biopharma's FY 2019 Performance

The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?

Snapshot: September Highlights

A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.

COVID-19 Global Perspective

Infographic: As the novel coronavirus continues to cause disruption and leave casualties across the globe, In Vivo has taken a look at the activities of the life sciences sector in response. Here is a breakdown of biopharma and medtech research actions against COVID-19. 

Titans Of Pharma 2020: 15 Leading CEOs Bag $266m In Compensation

See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.

See All
UsernamePublicRestriction

Register